Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Registration of Oral Hedgehog Inhibitors Vismodegib and Sonidegib in the Treatment of Advanced and Multiple Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

Next Previous
Trial Profile

Registration of Oral Hedgehog Inhibitors Vismodegib and Sonidegib in the Treatment of Advanced and Multiple Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonidegib (Primary) ; Vismodegib (Primary)
  • Indications Basal cell cancer; Basal cell nevus syndrome; Carcinoma; Skin cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Apr 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
  • 04 Apr 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2026.
  • 25 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top